CN105380261B - 一种含有寡肽的保肝护肝配方食品及其制备方法 - Google Patents
一种含有寡肽的保肝护肝配方食品及其制备方法 Download PDFInfo
- Publication number
- CN105380261B CN105380261B CN201510671040.3A CN201510671040A CN105380261B CN 105380261 B CN105380261 B CN 105380261B CN 201510671040 A CN201510671040 A CN 201510671040A CN 105380261 B CN105380261 B CN 105380261B
- Authority
- CN
- China
- Prior art keywords
- liver
- vitamin
- oligopeptide
- oligopeptides
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 64
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 64
- 210000004185 liver Anatomy 0.000 title claims abstract description 43
- 235000013305 food Nutrition 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 38
- 235000020251 goat milk Nutrition 0.000 claims abstract description 25
- 229960003080 taurine Drugs 0.000 claims abstract description 19
- 102000014171 Milk Proteins Human genes 0.000 claims abstract description 17
- 108010011756 Milk Proteins Proteins 0.000 claims abstract description 17
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 11
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 11
- 239000011720 vitamin B Substances 0.000 claims abstract description 9
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000661 sodium alginate Substances 0.000 claims abstract description 8
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 8
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 8
- 239000002131 composite material Substances 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 7
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 4
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 4
- 238000009472 formulation Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 21
- 244000068988 Glycine max Species 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 235000019419 proteases Nutrition 0.000 claims description 4
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 238000002523 gelfiltration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000007974 sodium acetate buffer Substances 0.000 claims description 3
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 238000005238 degreasing Methods 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 12
- 238000010521 absorption reaction Methods 0.000 abstract description 11
- 208000010706 fatty liver disease Diseases 0.000 abstract description 10
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 10
- 208000004930 Fatty Liver Diseases 0.000 abstract description 9
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 9
- 229920001231 Polysaccharide peptide Polymers 0.000 abstract description 9
- 108010022457 polysaccharide peptide Proteins 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 208000034189 Sclerosis Diseases 0.000 abstract description 5
- 230000002440 hepatic effect Effects 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 231100000614 poison Toxicity 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- 210000005229 liver cell Anatomy 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 150000003384 small molecules Chemical class 0.000 abstract description 3
- 239000003440 toxic substance Substances 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 210000003494 hepatocyte Anatomy 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 231100000753 hepatic injury Toxicity 0.000 description 18
- 230000009102 absorption Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 102000040350 B family Human genes 0.000 description 6
- 108091072128 B family Proteins 0.000 description 6
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 150000005693 branched-chain amino acids Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 238000003911 water pollution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于食品生产技术领域，具体涉及一种含有寡肽的保肝护肝配方食品及其制备方法。本发明所述食品的配方配比为：大豆蛋白寡肽25％～35％，云芝糖肽18％～22％，羊奶蛋白寡肽25％～35％，海藻酸钠8％～13％，牛磺酸3％～6％，水苏糖3％～5％，复合B族维生素0.05％～0.1％，配方的特点是小分子寡肽能快速吸收，迅速补充肝脏所需营养成分，强化肝脏营养，帮助修复受损肝细胞，促进肝细胞再生，并提高机体免疫力，增强肝脏自身的抵抗能力，还能抑制有害元素在体内的吸收，减轻肝脏的解毒负担，同时帮助清除体内脂类及胆固醇，防止脂肪在肝脏堆积，有效预防脂肪肝、肝硬化等化学性肝损伤的形成，且安全，无任何毒副作用。
Description
技术领域
本发明属于食品生产技术领域，具体涉及一种含有寡肽的保肝护肝配方食品及其制备方法。
背景技术
肝脏是人体最大的消化器官，在人体内起着中央化学处理器的作用，即吸收来自小肠血液中的各类营养物质，分解各种不利的毒物并排出体外。近年来，酒精肝、脂肪肝等化学性肝损伤已成为了一种常见疾病，我国肝损伤患者日益增多。严重的环境污染以及不良的生活习惯等都是造成肝损伤的原因，工业废气、废水造成的空气污染，水体污染，导致各种各样的化学毒物进入人体，侵害肝脏；大量饮酒、熬夜、过度疲劳等不良生活习惯也会增加肝脏负担，造成肝损伤，这也是都市人群脂肪肝比例居高不下的原因，脂肪肝又会转化成酒精性肝炎，进而发展成肝硬化。肝损伤的致病源广泛的存在于生活中，无孔不入，防不胜防，对肝脏问题必须引起足够的重视。
化学性肝损伤主要与自由基损伤、抗氧化体系不足或耗竭、磷脂的崩解、钙超载、免疫力低下等有关，它是每个生活中污染环境下的人不得不面对的问题，不仅是肝损伤患者，健康人群也应该提高警惕，积极预防化学性肝损伤。目前患者大多通过吃药类治疗化学性肝损伤，但是药三分毒，而药物的毒性大部分是通过肝脏来降解，这样在治疗的同时也加重肝脏的负担，最终会导致恶性循环。所以补充保肝护肝的功能食品，通过提高肝脏的免疫力，保护、修复肝细胞，安全有效的来预防及辅助治疗肝损伤是最科学的应对肝损伤的方法。
寡肽是由2～20个氨基酸残基通过肽键连接成的肽，具有重要的生理功能，其中高F值寡肽经大量实验证实具有保护肝功能的作用。高F值寡肽是由3～7个氨基酸残基组成的混合小肽体系，F值即在寡肽中支链氨基酸与芳香族氨基酸含量摩尔数之比，高F值寡肽是指寡肽中支链氨基酸与芳香族氨基酸的比值远高于人体中这两类氨基酸比值模式的寡肽。高F值寡肽具有消除或减轻肝性脑病症状、改善肝功能和改善多种病人蛋白质营养失常状态以及抗疲劳等功能。目前高F值寡肽除被广泛的用于制作治疗肝类疾病的药物以外，也被用作保肝、护肝功能性食品。
发明内容
本发明需要解决的问题是提供一种能对抗及预防化学性肝损伤、保护肝功能的配方食品及其制备的方法。本发明以大豆高F值寡肽、羊奶蛋白寡肽、云芝糖肽为主要原料，通过植物、动物、微生物三类肽的科学配比，相互作用，并配以海藻酸钠、牛磺酸、水苏糖、B族维生素等功能成分，提供了一种保护肝功能，预防及辅助治疗肝损伤的功能食品。
本发明的技术方案：
本发明所述含有寡肽的保肝护肝的配方食品，其配方原料包括以下成分：大豆蛋白寡肽、羊乳蛋白寡肽、云芝糖肽、海藻酸钠、牛磺酸、水苏糖、复合维生素B；其配方配比为：大豆蛋白寡肽25％～35％，云芝糖肽18％～22％，羊奶蛋白寡肽25％～35％，海藻酸钠8％～13％，牛磺酸3％～6％，水苏糖3％～5％，复合B族维生素0.05％～0.1％(包括维生素B1、维生素B2、维生素B6、维生素B12、烟酸、泛酸、叶酸)。
本发明所述含有寡肽的保肝护肝的配方食品，其制备方法包括以下步骤：
本发明所用的大豆蛋白寡肽分离自大豆多肽，所用的大豆多肽由湖北巨胜科技有限公司提供；所用制备羊奶蛋白寡肽的羊乳由陕西金牛乳业提供；所用云芝糖肽由盐城市芝庆堂有限公司提供。
1、大豆寡肽的分离：取大豆多肽加蒸馏水搅拌均匀，使得底物浓度为2％-5％，加入1％-3％活化好的木瓜蛋白酶，保持温度38℃，超声辅助酶解3-5小时，然后移至90-95℃水浴，保温10min灭酶活，将酶解液以4000r/min，离心15min，取上清液，调节上清液pH2～4值，按固液比1:(10-30)加入活性炭，40-50℃水浴吸附2-3小时，然后4000r/min，离心15min，将处理好的酶解液，用旋转蒸发仪浓缩至浸膏状，取出放入冻干机，冷冻干燥，打粉，即为大豆寡肽，所得的大豆寡肽F值大于20，为高F值寡肽；
2、羊奶蛋白寡肽制备：新鲜羊乳过滤除杂，在2-5℃下，4000r/min，离心20min，脱脂处理，50-55℃预热，并调节pH值到4.6，静止30min，4000r/min，离心15min，弃去上清液，沉淀分别用pH4.3和pH4.6的醋酸-醋酸钠缓冲液洗涤2次，洗涤后4000r/min离心15min，所得沉淀物即为羊奶蛋白粗品；称取羊奶蛋白粗品，加入蒸馏水搅拌溶解，使得浓度为10％-15％，调节pH至7.0～8.0，95℃加热5min，冷却到30-35℃，加入经过发酵加工制得的碱性蛋白酶和风味蛋白酶恒温水解，并将pH值保持在7.0～8.0范围内，超声辅助酶解4-6h后，95℃灭酶活10min，冷却，经膜分离后按料液比1:(20-50)加入活性炭，40-50℃水浴吸附2-3小时，4000r/min离心15min，凝胶过滤，旋转蒸发浓缩，冷冻干燥即得羊奶蛋白寡肽粉，所得的羊奶蛋白寡肽F值大于20；
3、按配方比例称取制备好的大豆寡肽粉、羊奶蛋白寡肽粉，与云芝糖肽、海藻酸钠、牛磺酸、水苏糖、复合B族维生素，混合均匀，分装即得。
下面结合本发明的原料，进一步说明本发明的功效：
大豆高F值寡肽：大豆寡肽具有高营养性，是一种具有极强活性和多样性的小分子活性肽，具有降血压、降血脂，防止动脉粥样硬化、心脏病、血栓等功效。它不需要消化可以直接吸收，直接进入细胞，发挥生理作用，且具有100％吸收的特点。能够快速补充人体的氮源，恢复体力，解除疲劳，高F值寡肽中高比例的支链氨基酸是不需要在肝脏代谢分解的必需氨基酸，可以改善肝、肾、胃肠疾病患者的营养，是肝损伤患者良好的营养补充剂，同时它可以阻止人体对胆固醇的吸收，促进脂肪代谢，抗氧化，清除体内自由基，并阻止新自由基的生成，有效的防止脂肪肝、肝硬化等化学性肝损伤，保护肝脏机能。
羊奶蛋白寡肽：羊奶中含有丰富的酪蛋白和乳清蛋白，用新鲜羊奶制备的寡肽，可以高效吸收，补充人体膳食蛋白，并能够帮助降低人体胆固醇，预防心脑血管疾病，提高机体免疫力。
云芝糖肽：云芝糖肽是从担子菌纲多孔菌科云芝或培养的菌丝中提取的具有多种药理作用的多糖类生物效应剂。具有明显的抗肿瘤、镇静、免疫调节、抗缺氧、促进多种细胞因子、抗乙肝病毒产生等作用。
海藻酸钠：海藻酸钠是海洋膳食纤维，具有独特的营养价值，它能够与有机物结合，降低血清和肝脏中的胆固醇，抑制总脂肪和总脂肪酸浓度上升，还能延缓脂类物质的消化吸收过程，防止脂肪在肝脏累积，造成脂肪肝，还可以改善营养物质的消化与吸收，同时还有抑制放射性锶、镉等有害元素在体内的吸收。
牛磺酸：牛磺酸又称α-氨基乙磺酸，它存在于哺乳动物的所有组织中，是心脏、视网膜、骨骼肌和白细胞中含量最丰富的游离氨基酸，具有强肝利胆、解热抗炎、降血压降血糖、改善内分泌状态增强人体免疫力等功能。牛磺酸在肝脏中的主要作用是与胆汁酸结合形成牛磺胆酸，牛磺胆酸能增加脂质和胆固醇的溶解性，起到预防脂肪肝、肝硬化、动脉粥样硬化等疾病的作用，除此之外，牛磺酸在肝脏中还具有其他重要的生理及药理功能，它可以参与稳定细胞膜，细胞渗透压调节，抗氧化，解毒等，临床实验证明，牛磺酸通过抗氧化作用对肝脏病例如炎症、凋亡、纤维化具有较好的治疗效果，所以保持胞内高浓度的牛磺酸对预防及辅助治疗肝损伤，保护肝脏功能具有重要的作用。细胞通过外源性摄取和内源性合成两种方式来维持细胞内高浓度的牛磺酸，人类和啮齿类动物机体合成牛磺酸的能力有限，所以肝脏中牛磺酸缺乏的主要原因是外源性牛磺酸摄入过少，并非内源性牛磺酸合成障碍。
水苏糖：水苏糖是一种新型功能性低聚糖，俗称“益生菌的食物”，具有延缓衰老、调节肠道微生态平衡、提高免疫力、排毒、降血压血脂的功能。水苏糖对人体胃肠道内的双歧杆菌、乳酸杆菌等有益菌群有着极明显的增殖作用，能迅速改善人体消化道内环境，调节微生态菌群平衡，促进形成有益菌在消化道内的优势地位，抑制产气产酸梭状芽胞杆菌等腐败菌的生成，另外产生大量生理活性物质，调节肠道pH值，杀灭致病菌，阻遏腐败产物生成，抑制内源致癌物的产生和吸收，并且分解衍生出多重免疫功能因子，提高机体的免疫力。
B族维生素：维生素B包括维生素B1、维生素B2、维生素B6、维生素B12、烟酸、泛酸、叶酸等，B族维生素是推动体内代谢，把糖、脂肪、蛋白质等转化成热量时不可缺少的物质。B族维生素和肝脏的关系也非常密切，缺少B族维生素，会导致细胞功能降低，引起代谢功能障碍。喝酒会导致肝损伤也和人体缺乏B族维生素有关，充足的B族维生素的补给，可以有效的治疗酒精肝炎和脂肪肝等肝脏疾病，因此，补充B族维生素，对预防和治疗肝损伤是非常重要的。
与现有技术相比本发明的有益效果是：小分子寡肽吸收速度快、效率高，迅速补充肝脏所需营养成分，强化肝脏营养，帮助修复受损肝细胞，促进肝细胞再生，并提高机体免疫力，增强肝脏自身的抵抗能力，配方还能抑制有害元素在体内的吸收，减轻肝脏的解毒负担，同时帮助清除体内脂类及胆固醇，防止脂肪在肝脏堆积，有效预防脂肪肝、肝硬化等化学性肝损伤的形成，且安全，无任何毒副作用。
具体实施方式
实施例1本发明所述含有寡肽的保肝护肝配方食品的制备方法：
(1)、大豆寡肽的分离：取大豆多肽加蒸馏水搅拌均匀，使得底物浓度为2％-5％，加入1％-3％活化好的木瓜蛋白酶，保持温度38℃，超声辅助酶解3-5小时，然后移至90-95℃水浴，保温10min灭酶活，将酶解液以4000r/min，离心15min，取上清液，调节上清液pH2～4值，按固液比1:(10-30)加入活性炭，40-50℃水浴吸附2-3小时，然后4000r/min，离心15min，将处理好的酶解液，用旋转蒸发仪浓缩至浸膏状，取出放入冻干机，冷冻干燥，打粉，即为大豆寡肽，所得的大豆寡肽F值大于20，为高F值寡肽；
2、羊奶蛋白寡肽制备：新鲜羊乳过滤除杂，在2-5℃下，4000r/min，离心20min，脱脂处理，50-55℃预热，并调节pH值到4.6，静止30min，4000r/min，离心15min，弃去上清液，沉淀分别用pH4.3和pH4.6的醋酸-醋酸钠缓冲液洗涤2次，洗涤后4000r/min离心15min，所得沉淀物即为羊奶蛋白粗品；称取羊奶蛋白粗品，加入蒸馏水搅拌溶解，使得浓度为10％-15％，调节pH至7.0～8.0，95℃加热5min，冷却到30-35℃，加入经过发酵加工制得的碱性蛋白酶和风味蛋白酶恒温水解，并将pH值保持在7.0～8.0的范围内，超声辅助酶解4-6h后，95℃灭酶活10min，冷却，经膜分离后按料液比1:(20-50)加入活性炭，40-50℃水浴吸附2-3小时，4000r/min离心15min，凝胶过滤，旋转蒸发浓缩，冷冻干燥即得羊奶蛋白寡肽粉，所得的羊奶蛋白寡肽F值大于20。
3、按配方比例称取制备好的大豆寡肽粉、羊奶蛋白寡肽粉，与云芝糖肽、海藻酸钠、牛磺酸、水苏糖、复合B族维生素，混合均匀，分装即得。
实施例2本发明所述含有寡肽的保肝护肝配方食品的人群功效实验
实验人群：实验分为的50-60岁组、60-70岁组、70-80岁组，每组选取生活习惯及生活水平相似的脂肪肝、酒精肝等肝损伤患者各10人。
实验方法：在实验开始之前通给各实验组人群进行一次肝功能检查，并记录检查结果。试验期间给实验人群服用本品，每日两次，每次1袋，30天后再次给试验人群进行一次肝功能检查，并与实验开始之前的结果比较，记录肝损伤的改善情况。
实验结果：
较好改善：肝损伤有明显改善
一般改善：肝损伤有轻微改善
无改善：肝损伤情况无任何改善
表1人群观察实验结果
由表1中数据可知，各实验组人群的肝损伤都有不同程度的改善，总改善率在70％-80％，说明本发明可以帮助修复肝损伤，恢复肝功能，并有预防化学性肝损伤的作用。
Claims (2)
1.一种含有寡肽的保肝护肝配方食品，其配方配比为：大豆蛋白寡肽25％～35％，云芝糖肽18％～22％，羊奶蛋白寡肽25％～35％，海藻酸钠8％～13％，牛磺酸3％～6％，水苏糖3％～5％，复合B族维生素0.05％～0.1％，复合B族维生素为维生素B1和维生素B2和维生素B6和维生素B12和烟酸和泛酸和叶酸。
2.根据权利1要求所述一种含有寡肽的保肝护肝配方食品的制备方法，其特征是由以下步骤构成：
(1)大豆寡肽的分离：取大豆多肽加蒸馏水搅拌均匀，使得底物浓度为2％-5％，加入1％-3％活化好的木瓜蛋白酶，保持温度38℃，超声辅助酶解3-5小时，然后移至90-95℃水浴，保温10min灭酶活，将酶解液以4000r/min，离心15min，取上清液，调节上清液pH2～4值，按固液比1:10-30加入活性炭40-50℃水浴吸附2-3小时，然后4000r/min，离心15min，将处理好的酶解液，用旋转蒸发仪浓缩至浸膏状，取出放入冻干机，冷冻干燥，打粉，即为大豆寡肽，所得的大豆寡肽F值大于20，为高F值寡肽；
(2)羊奶蛋白寡肽制备：新鲜羊乳过滤除杂，在2-5℃下，4000r/min，离心20min，脱脂处理，50-55℃预热，并调节pH值到4.6，静止30min，4000r/min，离心15min，弃去上清液，沉淀分别用pH4.3和pH4.6的醋酸-醋酸钠缓冲液洗涤2次，洗涤后4000r/min离心15min，所得沉淀物即为羊奶蛋白粗品；称取羊奶蛋白粗品，加入蒸馏水搅拌溶解，使得浓度为10％-15％，调节pH至7.0～8.0，95℃加热5min，冷却到30-35℃，加入经过发酵加工制得的碱性蛋白酶和风味蛋白酶恒温水解，并将pH值保持在7.0～8.0的范围内，超声辅助酶解4-6h后，95℃灭酶活10min，冷却，经膜分离后按料液比1:20-50加入活性炭，40-50℃水浴吸附2-3小时，4000r/min离心15min，凝胶过滤，旋转蒸发浓缩，冷冻干燥即得羊奶蛋白寡肽粉，所得的羊奶蛋白寡肽F值大于20；
(3)按权利要求1所述配方比例称取制备好的大豆寡肽粉、羊奶蛋白寡肽粉，与云芝糖肽、海藻酸钠、牛磺酸、水苏糖、复合B族维生素，混合均匀，分装即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510671040.3A CN105380261B (zh) | 2015-10-13 | 2015-10-13 | 一种含有寡肽的保肝护肝配方食品及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510671040.3A CN105380261B (zh) | 2015-10-13 | 2015-10-13 | 一种含有寡肽的保肝护肝配方食品及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105380261A CN105380261A (zh) | 2016-03-09 |
| CN105380261B true CN105380261B (zh) | 2018-09-07 |
Family
ID=55413516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510671040.3A Active CN105380261B (zh) | 2015-10-13 | 2015-10-13 | 一种含有寡肽的保肝护肝配方食品及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105380261B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109364236A (zh) * | 2018-09-12 | 2019-02-22 | 陈亮 | 一种黄精蛋白肽饮品配方及其制备工艺 |
| CN112972647B (zh) * | 2021-02-23 | 2021-10-22 | 广东海洋大学 | 一种组合物在防治酒精性脑损伤中的应用 |
| CN112870331B (zh) * | 2021-02-23 | 2021-10-15 | 广东海洋大学 | 一种防治酒精性肝损伤的组合物及其制备方法与应用 |
| CN114027357A (zh) * | 2021-12-09 | 2022-02-11 | 齐鲁工业大学 | 一种含有乳清寡肽的功能性乳制品及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004103391A1 (ja) * | 2003-05-22 | 2004-12-02 | Fuji Oil Company, Limited | 肝臓中の脂質代謝促進剤、肝臓中の脂質代謝促進健康食品及びその有効成分であるペプチド混合物の製造法 |
| CN101096698B (zh) * | 2007-07-18 | 2010-05-26 | 东北农业大学 | 大豆高f值寡肽的制备方法 |
| CN102077938B (zh) * | 2010-09-20 | 2013-03-20 | 王强 | 一种肝损伤患者专用的海洋特膳食品 |
| CN102160563B (zh) * | 2011-03-07 | 2012-09-26 | 西北农林科技大学 | 一种抗疲劳寡肽饼干的制备方法 |
| CN104172196B (zh) * | 2014-07-30 | 2016-08-24 | 广州金酮医疗科技有限公司 | 一种用于改善脂肪肝的营养组合物及其制备方法 |
-
2015
- 2015-10-13 CN CN201510671040.3A patent/CN105380261B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105380261A (zh) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104004813B (zh) | 一种香菇生物活性肽的制备 | |
| CN105380261B (zh) | 一种含有寡肽的保肝护肝配方食品及其制备方法 | |
| CN107668459A (zh) | 一种香菇小分子肽复配的固体饮料及其制备方法 | |
| CN102429235A (zh) | 一种具有缓解体力疲劳和增强免疫力功能的保健食品 | |
| CN104207150A (zh) | 大豆肽真菌多糖口服液及其制备方法 | |
| CN103653147A (zh) | 一种小麦肽抗疲劳保健饮料及其制备方法 | |
| CN106173829A (zh) | 一种营养米粉的加工方法 | |
| CN104855845A (zh) | 一种纳豆营养健康食品 | |
| CN106858595A (zh) | 一种烧伤专用型临床营养配方及其制备方法 | |
| CN112999261A (zh) | 一种舒缓动脉硬化的纳豆发酵组合物及其制备方法和应用 | |
| JP2006238730A (ja) | 肝機能強化性健康食品 | |
| US20210010048A1 (en) | Method of preparing corn glycopeptides, and product and use thereof | |
| CN112890064A (zh) | 一种复合胶原蛋白肽固体饮料及其制备方法 | |
| CN106359839A (zh) | 一种牡蛎肽的提取方法 | |
| CN114214366B (zh) | 一种预防和治疗贫血的小肽粉和血红素之肽红复方药物及其制备方法和应用 | |
| CN110313619A (zh) | 一种具有保肝护肝功效的复方肽及其制备方法 | |
| CN107890117A (zh) | 一种浓缩乳清蛋白复合低聚肽营养粉 | |
| KR102650031B1 (ko) | 반려동물 심장 기능 개선용 조성물 및 이를 포함하는 기능성 식품 | |
| CN102659917A (zh) | 一种从松花粉中分离制备粗蛋白及酶解肽类的方法 | |
| CN108201136A (zh) | 富铬营养强化剂及其制备方法 | |
| CN104082656B (zh) | 一种适合肝病病人的营养膳及其制作方法 | |
| CN109846046A (zh) | 一种提高免疫力的甘露糖-氨基酸复合物 | |
| CN110075280A (zh) | 一种层粘连蛋白肽复合口服剂及其制备方法 | |
| CN105077273A (zh) | 一种有助于手术病人恢复的保健食品 | |
| CN105995971A (zh) | 一种促进糖尿病康复的营养流食及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |